- Home
- CBIO vs VBF Comparison
CBIO vs VBF Comparison
Compare CBIO & VBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- VBF
- Stock Information
- Founded
- CBIO 2003
- VBF 1970
- Country
- CBIO United States
- VBF United States
- Employees
- CBIO N/A
- VBF N/A
- Industry
- CBIO
- VBF Trusts Except Educational Religious and Charitable
- Sector
- CBIO
- VBF Finance
- Exchange
- CBIO Nasdaq
- VBF Nasdaq
- Market Cap
- CBIO 173.5M
- VBF 177.1M
- IPO Year
- CBIO N/A
- VBF N/A
- Fundamental
- Price
- CBIO $12.94
- VBF $15.84
- Analyst Decision
- CBIO Strong Buy
- VBF
- Analyst Count
- CBIO 5
- VBF 0
- Target Price
- CBIO $25.60
- VBF N/A
- AVG Volume (30 Days)
- CBIO 99.7K
- VBF 45.5K
- Earning Date
- CBIO 07-31-2025
- VBF 01-01-0001
- Dividend Yield
- CBIO N/A
- VBF 5.18%
- EPS Growth
- CBIO N/A
- VBF N/A
- EPS
- CBIO N/A
- VBF N/A
- Revenue
- CBIO N/A
- VBF N/A
- Revenue This Year
- CBIO N/A
- VBF N/A
- Revenue Next Year
- CBIO N/A
- VBF N/A
- P/E Ratio
- CBIO N/A
- VBF N/A
- Revenue Growth
- CBIO N/A
- VBF N/A
- 52 Week Low
- CBIO $10.83
- VBF $13.68
- 52 Week High
- CBIO $21.40
- VBF $16.27
- Technical
- Relative Strength Index (RSI)
- CBIO 47.01
- VBF 69.10
- Support Level
- CBIO $12.03
- VBF $15.54
- Resistance Level
- CBIO $13.21
- VBF $15.98
- Average True Range (ATR)
- CBIO 0.85
- VBF 0.12
- MACD
- CBIO -0.07
- VBF 0.03
- Stochastic Oscillator
- CBIO 33.58
- VBF 78.13
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.